The Prognostic Power of PSA: What Ultra-Low Levels Reveal in mHSPC

home / investigator-perspectives / the-prognostic-power-of-psa-what-ultra-low-levels-reveal-in-mhspc

Neal D. Shore, MD, FACS, discusses how achieving ultra-low prostate-specific antigen (PSA) levels (<0.02 ng/mL) in patients with metastatic hormone-sensitive prostate cancer (mHSPC) treated with darolutamide plus androgen deprivation therapy in the ARANOTE trial correlates with improved clinical outcomes including progression-free survival.

© 2025 MJH Life Sciences

All rights reserved.